3 Fast Growing ASX Stocks With High Insider Ownership Worth A Closer Look

Central banks are moving in different directions, with some regions facing tighter policy expectations while others see more caution. That kind of split can reward companies that create their own growth through strong execution rather than relying on cheap money. Fast growing stocks with high insider ownership can be well aligned with that story. This article highlights three such stocks from the screener that merit a closer look.

The stocks in the article below are just a starting sample from this growth and insider-backed theme, and the full screen surfaced 99 more companies with equally interesting stories that are not covered here. To identify and analyze the most compelling ideas right now, head straight to the Fast Growing Stocks With High Insider Ownership screener.

Predictive Discovery (ASX:PDI)

Overview: Predictive Discovery is a West Africa focused gold company whose main asset is the Bankan Gold Project in north east Guinea, a large scale exploration and development project that aims to turn a 9.5 million ounce resource and 4.5 million ounces of reserves into long term production. The company also owns the producing Kiniero and Nampala mines, which provide an operating base to support Bankan and align with the growth and insider backed theme.

Market Cap: A$4.2b

Predictive Discovery draws interest because its Bankan Gold Project sits alongside two operating mines, giving you exposure to a potential new gold hub while Kiniero and Nampala already generate cash to help fund development. Analysts are optimistic about long term revenue and earnings potential. However, the company currently has no revenue at the group level and is investing heavily, which keeps funding risk front and centre. Recent updates on Bankan engineering work, contract awards and 2026 production guidance show execution is moving forward. A planned name change to PDI Gold Limited and governance changes point to a company gearing up for a bigger role in West African gold.

Predictive Discovery is working to turn a large Bankan resource into long-term production, while Kiniero and Nampala already keep the lights on. Get the full story behind that growth and funding trade off in the analysis report for Predictive Discovery

Build your own growth and insider backed shortlist

Predictive Discovery and the other two stocks in this article all surfaced from a single Simply Wall St screener, and you can spin up your own version in minutes. Use our customisable Screener to combine filters on growth, balance sheet strength and insider ownership, or start with any of our curated Investing Ideas as a ready made jumping off point.

Telix Pharmaceuticals (ASX:TLX)

Overview: Telix Pharmaceuticals is a commercial stage biopharmaceutical company that develops and sells radiopharmaceutical products that help doctors both see and treat cancers, with Illuccix already used globally for prostate cancer imaging and TLX591 in Phase 3 trials for advanced prostate cancer therapy. Its precision medicine and therapeutic radiopharmaceutical pipeline is the clearest link to the fast growing, insider backed theme. Manufacturing solutions provide support but are not the primary growth story.

Operations: Telix generates most of its revenue from the Precision Medicine segment at about US$621.9 million, with additional contributions from Manufacturing Solutions at about US$245.1 million and Therapeutics at about US$9.3 million.

Market Cap: A$5.6b

Telix Pharmaceuticals combines a commercial imaging franchise with a late stage radiopharmaceutical pipeline, which is a profile many investors look for in a fast growing, insider aligned stock. Products such as Illuccix generate substantial Precision Medicine revenue today, while TLX591 and TLX250 progress through Phase 3 trials in prostate and kidney cancer with recent updates, FDA alignment and new patient dosing events through mid 2026. At the same time, Telix is not yet profitable, carries higher risk funding and faces R&D, regulatory and pricing pressures that could affect margins if plans are not achieved. That mix of commercial traction and pipeline risk is what may make Telix worth a closer look for some investors.

Telix Pharmaceuticals looks like a classic revenue story whose pipeline risk is easy to misread. Before you assume the funding and trial pressures outweigh the upside, walk through the analyst forecasts for Telix Pharmaceuticals

Lindian Resources (ASX:LIN)

Overview: Lindian Resources is a Perth based explorer focused on the Kangankunde Rare Earths project in Malawi, a flagship rare earth development aimed at supplying key materials for EV motors, wind turbines and electronics. The company also explores for gold and bauxite in Tanzania, Guinea, Australia and Singapore, but Kangankunde is the main growth and management backed asset that aligns it with the fast growing, high insider ownership theme.

Market Cap: A$1.5b

Lindian Resources offers a pure play rare earths story built around Kangankunde, where management is working toward first concentrate production and a Stage 2 investment decision in Q4 2026, and backing that up with a plan to own 100% of the SARECO processing facility in Kazakhstan for downstream exposure. At the same time, the company is currently loss making, has very small revenue, relies heavily on external funding and has a relatively new board with no independent directors. These factors raise governance and potential dilution questions. For investors interested in stories tied to EVs and clean energy materials, Lindian provides a focused but higher risk way to gain that exposure.

Lindian Resources is attempting to connect rare earths growth hopes with a funding-hungry, early-stage project story. Before you assume that risk is too hard to price, unpack the analyst forecasts for Lindian Resources

Seeking Alternatives Before Momentum Flies Past

Fresh breakouts and under the radar stocks rarely stay quiet for long. Momentum builds, prices move and late entries get caught chasing. Scan these ideas while it matters and consider them before momentum advances further.

• Target dependable income streams by scanning the 3 dividend fortresses that aim to keep cash flow flying even when other payouts are dropping.
• Look at potential future enablers of AI before the crowd notices by reviewing the 56 AI infrastructure stocks powering data centers, chips and high speed networks.
• Track the metals momentum by checking the curated 9 top copper producer stocks that could benefit if demand for electrification keeps building.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com